Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 

Saved Queries

Sign in to use this feature.

Search Filter Reset All

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
Add Subjects Reset
Select Subjects

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
Add Journals Reset
Select Journals

Article Types

remove_circle_outline
remove_circle_outline
remove_circle_outline
Add Article Types Reset
Select Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
Add Countries / Regions Reset
Select Countries / Regions
Update Search
share announcement

Search Results (4)

Search Parameters:
Keywords = Radiation recall dermatitis

Order results
Result details
Results per page
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
4 pages, 1500 KiB  
Interesting Images
An Unusual and Exaggerated Local Cutaneous Reaction Following Re-Irradiation and Fulvestrant Administration: A Clinical Conundrum
by Valentina Zagardo, Dorotea Sciacca and Gianluca Ferini
Diagnostics 2025, 15(8), 1017; https://doi.org/10.3390/diagnostics15081017 - 16 Apr 2025
Cited by 1 | Viewed by 519
Abstract
A 56-year-old female with a history of Luminal A breast cancer, previously treated with surgery, radiotherapy, and systemic therapy, underwent palliative re-irradiation in November 2024 for painful bone metastases. Three weeks later, following the initiation of Fulvestrant, she developed a grade 3 erythematous [...] Read more.
A 56-year-old female with a history of Luminal A breast cancer, previously treated with surgery, radiotherapy, and systemic therapy, underwent palliative re-irradiation in November 2024 for painful bone metastases. Three weeks later, following the initiation of Fulvestrant, she developed a grade 3 erythematous reaction localized to the re-irradiated area. The reaction persisted with minimal improvement over two months, despite symptomatic management. No infectious or allergic etiologies were identified, and dosimetric analysis confirmed that the delivered radiation dose to the skin was insufficient to directly induce such a reaction. Notably, the erythema was most pronounced along a pre-existing surgical scar, suggesting a localized inflammatory response. Given the temporal relationship with Fulvestrant administration, we hypothesize a drug-induced recall-like phenomenon, though no previous reports have specifically linked Fulvestrant to such an event. This case underscores the need for awareness of unexpected cutaneous reactions following re-irradiation and highlights the potential role of systemic therapies in modulating local tissue responses. Full article
(This article belongs to the Section Medical Imaging and Theranostics)
►▼ Show Figures

Figure 1

6 pages, 1637 KiB  
Case Report
Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy
by Caroline J. Cushman, Fuad Abaleka, Andrew F. Ibrahim, Kiran Yalamanchili, Seshadri Thirumala and Donald Quick
Reports 2024, 7(4), 91; https://doi.org/10.3390/reports7040091 - 4 Nov 2024
Viewed by 1130
Abstract
Background and Clinical Significance: Radiation recall dermatitis (RRD) following immune checkpoint inhibitor (ICI) therapy has been infrequently reported. Case Presentation: We present a 47-year-old female patient who developed RRD of the breast following three doses of pembrolizumab administered as an adjuvant treatment post-nephrectomy [...] Read more.
Background and Clinical Significance: Radiation recall dermatitis (RRD) following immune checkpoint inhibitor (ICI) therapy has been infrequently reported. Case Presentation: We present a 47-year-old female patient who developed RRD of the breast following three doses of pembrolizumab administered as an adjuvant treatment post-nephrectomy for Stage III renal cell carcinoma (RCC). Notably, the affected breast had previously undergone external beam radiotherapy 247 weeks earlier for Stage IA invasive ductal carcinoma. She had received no prior chemotherapy at any point. RRD manifested as breast induration, erythema, and peau d’orange, and contraction of breast volume was noted following three cycles of pembrolizumab on week 17 (400 mg dose every 6 weeks). The dermatitis responded rapidly to systemic corticosteroids and no treatment interruption was needed. Conclusions: To date, this is the longest reported interval from completion of radiotherapy to RRD. A literature search underscores the variability in presentation and management of ICI-associated RRD. Full article
(This article belongs to the Special Issue Advancements in Clinical Applications of Immune Checkpoint Inhibitors)
►▼ Show Figures

Figure 1

3 pages, 330 KiB  
Article
Radiation Recall Dermatitis with Azithromycin
by O. Vujovic
Curr. Oncol. 2010, 17(4), 119-121; https://doi.org/10.3747/co.v17i4.488 - 1 Aug 2010
Cited by 15 | Viewed by 847
Abstract
Radiation recall is a well-known phenomenon that involves the “recall” of an acute inflammatory reaction in a previously irradiated region after administration of certain drugs. The most common type of radiation recall is radiation recall dermatitis, which involves the reoccurrence of an acute [...] Read more.
Radiation recall is a well-known phenomenon that involves the “recall” of an acute inflammatory reaction in a previously irradiated region after administration of certain drugs. The most common type of radiation recall is radiation recall dermatitis, which involves the reoccurrence of an acute inflammatory skin reaction in previously irradiated skin. Most radiation recall reactions are attributable to chemotherapeutic agents. One previously reported case of radiation recall dermatitis occurred after administration of an antibiotic. The present case report is the second of radiation recall dermatitis involving an antibiotic: azithromycin. Full article
10 pages, 1011 KiB  
Article
Radiation Recall Dermatitis: Case Report and Review of the Literature
by A. E. Hird, J. Wilson, S. Symons, E. Sinclair, M. Davis and E. Chow
Curr. Oncol. 2008, 15(1), 53-62; https://doi.org/10.3747/co.2008.201 - 1 Jan 2008
Cited by 62 | Viewed by 3023
Abstract
“Radiation recall”—also called “radiation recall dermatitis”—has been defined as the “recalling” by skin of previous radiation exposure in response to the administration of certain response-inducing drugs. Although the phenomenon is relatively well known in the medical world, an exact cause has not been [...] Read more.
“Radiation recall”—also called “radiation recall dermatitis”—has been defined as the “recalling” by skin of previous radiation exposure in response to the administration of certain response-inducing drugs. Although the phenomenon is relatively well known in the medical world, an exact cause has not been documented. Here, we report a rare occurrence of the radiation recall phenomenon in a breast cancer patient after palliative radiotherapy for bone, brain, and orbital metastases. Full article
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying article 1-50 on page 1 of 1.
Back to TopTop